Time-dependent changes in the brain arachidonic acid cascade during cuprizone-induced demyelination and remyelination

Kam, 2000, Cyclo-oxygenase isoenzymes: physiological and pharmacological role, Anaesthesia, 555, 442, 10.1046/j.1365-2044.2000.01271.x Katori, 2000, Cyclooxygenase-2: its rich diversity of roles and possible application of its selective inhibitors, Inflamm. Res., 498, 367, 10.1007/s000110050605 Bosetti, 2007, Arachidonic acid metabolism in brain physiology and pathology: lessons from genetically altered mouse models, J. Neurochem., 1023, 577, 10.1111/j.1471-4159.2007.04558.x Dore-Duffy, 1986, Prostagland in release in multiple sclerosis: correlation with disease activity, Neurology, 3612, 1587, 10.1212/WNL.36.12.1587 Dore-Duffy, 1991, Cerebrospinal fluid eicosanoid levels: endogenous PGD2 and LTC4 synthesis by antigen-presenting cells that migrate to the central nervous system, Neurology, 412, 322, 10.1212/WNL.41.2_Part_1.322 Folco, 2006, Eicosanoid transcellular biosynthesis: from cell–cell interactions to in vivo tissue responses, Pharmacol. Rev., 583, 375, 10.1124/pr.58.3.8 Sun, 2007, The roles of NADPH oxidase and phospholipases A2 in oxidative and inflammatory responses in neurodegenerative diseases, J. Neurochem., 1031, 1 Huterer, 1995, Alterations in the activity of phospholipases A2 in postmortem white matter from patients with multiple sclerosis, Neurochem. Res., 2011, 1335, 10.1007/BF00992509 Marusic, 2008, Blockade of cytosolic phospholipase A2 alpha prevents experimental autoimmune encephalomyelitis and diminishes development of Th1 and Th17 responses, J. Neuroimmunol., 2041–2, 29, 10.1016/j.jneuroim.2008.08.012 Kalyvas, 2004, Cytosolic phospholipase A2 plays a key role in the pathogenesis of multiple sclerosis-like disease, Neuron, 413, 323, 10.1016/S0896-6273(04)00003-0 Marusic, 2005, Cytosolic phospholipase A2 alpha-deficient mice are resistant to experimental autoimmune encephalomyelitis, J. Exp. Med., 2026, 841, 10.1084/jem.20050665 Hiremath, 1998, Microglial/macrophage accumulation during cuprizone-induced demyelination in C57BL/6 mice, J. Neuroimmunol., 921–2, 38, 10.1016/S0165-5728(98)00168-4 Matsushima, 2001, The neurotoxicant, cuprizone, as a model to study demyelination and remyelination in the central nervous system, Brain Pathol., 111, 107 Meier, 2004, Myelination in the hippocampus during development and following lesion, Cell. Mol. Life Sci., 619, 1082, 10.1007/s00018-004-3469-5 Marriott, 2008, Leukemia inhibitory factor signaling modulates both central nervous system demyelination and myelin repair, Glia, 566, 686, 10.1002/glia.20646 Toscano, 2007, Differential gene expression patterns in cyclooxygenase-1 and cyclooxygenase-2 deficient mouse brain, Genome Biol., 81, R14, 10.1186/gb-2007-8-1-r14 Livak, 2001, Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method, Methods, 254, 402, 10.1006/meth.2001.1262 Radin, 1981, Extraction of tissue lipids with a solvent of low toxicity, Methods Enzymol., 72, 5, 10.1016/S0076-6879(81)72003-2 Aid, 2007, Gene expression of cyclooxygenase-1 and Ca(2+)-independent phospholipase A(2) is altered in rat hippocampus during normal aging, Brain Res. Bull., 731–3, 108, 10.1016/j.brainresbull.2007.02.015 Gudi, 2009, Regional differences between grey and white matter in cuprizone induced demyelination, Brain Res., 1283, 127, 10.1016/j.brainres.2009.06.005 Skripuletz, 2010, Beneficial effects of minocycline on cuprizone induced cortical demyelination, Neurochem. Res., 359, 1422, 10.1007/s11064-010-0202-7 Reder, 1995, Eicosenoids modify experimental allergic encephalomyelitis, Am. J. Ther., 29, 711, 10.1097/00045391-199509000-00020 Ni, 2007, COX-2 inhibitors ameliorate experimental autoimmune encephalomyelitis through modulating IFN-gamma and IL-10 production by inhibiting T-bet expression, J. Neuroimmunol., 1861–2, 94, 10.1016/j.jneuroim.2007.03.012 Miyamoto, 2006, Selective COX-2 inhibitor celecoxib prevents experimental autoimmune encephalomyelitis through COX-2-independent pathway, Brain, 129, 1984, 10.1093/brain/awl170 Pollak, 2002, Experimental autoimmune encephalomyelitis-associated behavioral syndrome as a model of ‘depression due to multiple sclerosis’, Brain Behav. Immun., 165, 533, 10.1016/S0889-1591(02)00010-7 Aid, 2008, Neuroinflammatory response to lipopolysaccharide is exacerbated in mice genetically deficient in cyclooxygenase-2, J. Neuroinflammation, 5, 17, 10.1186/1742-2094-5-17 Choi, 2008, Genetic deletion or pharmacological inhibition of cyclooxygenase-1 attenuate lipopolysaccharide-induced inflammatory response and brain injury, Faseb J., 225, 1491, 10.1096/fj.07-9411com Manev, 1998, Early upregulation of hippocampal 5-lipoxygenase following systemic administration of kainate to rats, Restor. Neurol. Neurosci., 122–3, 81 Simmet, 1990, Cysteinyl-leukotriene production during limbic seizures triggered by kainic acid, Brain Res., 5151–2, 79, 10.1016/0006-8993(90)90579-Z Kalyvas, 2009, Differing roles for members of the phospholipase A2 superfamily in experimental autoimmune encephalomyelitis, Brain, 132, 1221, 10.1093/brain/awp002 Kokotos, 2004, Inhibition of group IVA cytosolic phospholipase A2 by novel 2-oxoamides in vitro, in cells, and in vivo, J. Med. Chem., 4714, 3615, 10.1021/jm030485c Pinto, 2003, Extracellular phospholipase A2 inhibitors suppress central nervous system inflammation, Glia, 443, 275, 10.1002/glia.10296 Cunningham, 2006, Secreted phospholipase A2 activity in experimental autoimmune encephalomyelitis and multiple sclerosis, J. Neuroinflammation, 3, 26, 10.1186/1742-2094-3-26 Rainsford, 2007, Anti-inflammatory drugs in the 21st century, Subcell. Biochem., 42, 3, 10.1007/1-4020-5688-5_1